Drug Profile
VAK 694
Alternative Names: NVP-VAK694; VAK694Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Novartis
- Class Antiallergics; Antibodies
- Mechanism of Action Interleukin 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Seasonal allergic rhinitis
Most Recent Events
- 31 Oct 2011 Novartis completes a phase II trial in Seasonal allergic rhinitis in United Kingdom (NCT01018693)
- 28 Feb 2011 Novartis completes a phase II trial in Seasonal allergic rhinitis in USA & Canada (NCT00929968)
- 12 May 2010 Novartis completes enrolment in its phase II trial (NCT01018693) for Seasonal allergic rhinitis in the UK